Janux Therapeutics discontinues JANX008 after Phase 1a data show limited efficacy despite favorable safety, reinforcing focus on other TRACTr pipeline candidates.
Written By: Mahathi Palivela, PharmD
Reviewed By: Pharmacally Editorial Team
Janux Therapeutics, Inc. has discontinued further clinical development of JANX008, its EGFR-targeted tumor-activated T cell engager (TRACTr), following completion of the Phase 1a dose-escalation and expansion study (ENGAGER-JANX008-101, NCT05783622) in approximately 40 patients with EGFR-expressing solid tumors, including non-small cell lung cancer and colorectal cancer.
While some patients demonstrated durable responses and disease control with extended follow-up, with objective response rates of approximately 20–25% in select cohorts, the overall magnitude and consistency of activity did not meet the company’s predefined thresholds for advancement, particularly relative to other pipeline assets.
The trial confirmed a favorable safety profile for the TRACTr platform. Cytokine release syndrome was infrequent and mostly Grade 1, supporting outpatient dosing. JANX008 was also associated with minimal gastrointestinal, dermatologic, and subcutaneous adverse events typically seen with EGFR-targeted therapies. However, musculoskeletal toxicities were dose-limiting, constraining the therapeutic window despite dosing levels sufficient to evaluate activity.
Janux stated that the decision is specific to JANX008 and does not affect its broader TRACTr platform or ongoing programs, including JANX007 and JANX009. The company indicated that insights from the study will inform future development of EGFR- and TRACTr-based therapies.
David Campbell, Ph.D., President and Chief Executive Officer of Janux, stated: “The decision to discontinue JANX008 reflects our disciplined approach to prioritizing pipeline programs that meet high standards for safety, efficacy, and differentiation.”
William Go, M.D., Ph.D., Chief Medical Officer, added: “The study demonstrated objective responses and disease control in some patients, while providing key insights into how target biology and design strategies shape the therapeutic window to inform further development.”
Reference
About the Writer
Mahathi Palivela is pursuing PharmD and has a strong interest in Clinical Pharmacy and Patient safety. She is passionate about handling and analyzing patient data, and translating clinical insights into clear, meaningful summaries. She aims to apply this interest in Medical Writing and Pharmacovigilance, focusing on improving patient outcomes through careful data interpretation and communication.